Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2019 Dec;7(Suppl 8):S275.
doi: 10.21037/atm.2019.11.138.

Can immune biomarkers predict benefit from targeted agents in metastatic renal cell carcinoma?

Renate Pichler  1 , Manuela Schmidinger  2
Affiliations
Editorial

Can immune biomarkers predict benefit from targeted agents in metastatic renal cell carcinoma?

Renate Pichler et al. Ann Transl Med. 2019 Dec.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: R Pichler: Honoraria for lectures and advisory boards: Pfizer, BMS, Roche, Ipsen, MSD, Merck, EISAI. Travel grants: BMS, Pfizer, Roche, Pierre Fabre. Research grants: Astellas, Agea Pharma. M Schmidinger: Honoraria for lectures and advisory boards: Pfizer, BMS, Novartis, Roche, Ipsen, Exelixis, EISAI, EUSA, Stellas. Research Grants: Roche, Pfizer. Travel grants: Roche, Ipsen, Pfizer.

Comment on

Similar articles

See all similar articles

References

    1. Flaifel A, Xie W, Braun DA, et al. PD-L1 Expression and Clinical Outcomes to Cabozantinib, Everolimus, and Sunitinib in Patients with Metastatic Renal Cell Carcinoma: Analysis of the Randomized Clinical Trials METEOR and CABOSUN. Clin Cancer Res 2019;25:6080-8. 10.1158/1078-0432.CCR-19-1135 - DOI - PMC - PubMed
    1. Choueiri TK, Escudier B, Powles T, et al. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. Lancet Oncol 2016;17:917-27. 10.1016/S1470-2045(16)30107-3 - DOI - PubMed
    1. Choueiri TK, Halabi S, Sanford BL, et al. Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial. J Clin Oncol 2017;35:591-7. 10.1200/JCO.2016.70.7398 - DOI - PMC - PubMed
    1. Lalani AA, McGregor BA, Albiges L, et al. Systemic Treatment of Metastatic Clear Cell Renal Cell Carcinoma in 2018: Current Paradigms, Use of Immunotherapy, and Future Directions. Eur Urol 2019;75:100-10. 10.1016/j.eururo.2018.10.010 - DOI - PubMed
    1. Motzer RJ, Tannir NM, McDermott DF, et al. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. N Engl J Med 2018;378:1277-90. 10.1056/NEJMoa1712126 - DOI - PMC - PubMed